Online Inquiry
CHEK2 (-/-); TP53 (-/-) Cell Line
SPL-00961
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| CHEK2 (-/-); TP53 (-/-) |
| Target Information | |
|---|---|
| Target Name | Chk2 |
| Gene Abbr. | CHEK2 |
| Gene ID | 11200 |
| Full Name | checkpoint kinase 2 |
| Alias | CDS1, CHK2, HuCds1, LFS2, PP1425 |
| Species | Human |
| Genomic Locus | 22q12.1;17p13.1 |
| Introduction | In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]. |
| Product Details | |
|---|---|
| Cell Line Model | HCT116 |
| Genotype | CHEK2 (-/-); TP53 (-/-) |
| Description | CHEK2 (-/-); TP53 (-/-) |
| Parental ATCC ID | CCL-247 |
| STR Profile | Amelogenin: X,Y; CSF1PO: 7,10; D13S317: 10,12; D16S539: 11,13; D5S818: 10,11; D7S820: 11,12; THO1: 8,9; TPOX: 8,9; vWA: 17,22; ATCC |
| Disease | Colorectal carcinoma |
| Tissue | Colon |
| Gender | Male |
| Key Endogenous Mutations | CDKN2A, CTNNB1, KRAS, PIK3CA, MLH1 |
| CVT Selection Condition | G418 resistant - 0.4 mg/mL |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
| Culture Medium | RPMI 1640 including 2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.